VOGT-KOYANAGI-HARADA SYNDROME - CLINICAL COURSE, THERAPY, AND LONG-TERM VISUAL OUTCOME
VOGT-KOYANAGI-HARADA SYNDROME - CLINICAL COURSE, THERAPY, AND LONG-TERM VISUAL OUTCOME
复制标题
DOI：
10.1001/archopht.1991.01080050096037
复制
发表时间：
1991-05-01
影响因子：
--
通讯作者：
GASS, JDM
中科院分区：
文献类型：
--
作者：
RUBSAMEN, PE;GASS, JDM
我们回顾了1969年3月至1990年2月期间在巴斯科姆帕尔默眼科研究所就诊的26例Vogt-Koyanagi-Harada综合征患者的资料。视力结果良好，44只眼中有29只（66%）的最终视力优于20/30,44只眼中只有3只（7%）的最终视力低于20/400。不良预后与脉络膜新生血管膜或慢性葡萄膜炎的发展有关。所有患者均接受全身皮质类固醇治疗。皮质类固醇治疗平均为6个月，但慢性葡萄膜炎患者延长治疗时间（48个月）。21例患者中有9例（43%）在前3个月内复发，通常与类固醇剂量的迅速减少有关。我们建议对Vogt-Koyanagi-Harada综合征患者早期积极使用全身皮质类固醇，并在出现症状后6个月内逐渐减少药物剂量。
We reviewed data from 26 patients with Vogt-Koyanagi-Harada syndrome who presented at the Bascom Palmer Eye Institute between March 1969 and February 1990. Visual outcomes were good, with final visual acuity of better than 20/30 in 29 (66%) of 44 eyes and of worse than 20/400 in only three (7%) of 44 eyes. A poor prognosis was associated with the development of choroidal neovascular membranes or chronic uveitis. All patients were treated with systemic corticosteroids. Corticosteroid therapy averaged 6 months, but was prolonged (48 months) in patients who developed chronic uveitis. Disease recurred in nine (43%) of 21 patients in the first 3 months, usually in association with a rapid tapering of steroid dosage. We recommend the early, aggressive use of systemic corticosteroids in patients with Vogt-Koyanagi-Harada syndrome and a gradual tapering of drug dosage for 6 months after presentation.